Champaign has a new pair of twin towers coming to Green Street next season. Former Arkansas center Zvonimir Ivišić has joined forces with his twin brother Tomislav after committing to Illinois on ...

Novo Nordisk has quickly expanded its discounted Wegovy program, now offering all eligible cash-paying customers its popular weight-loss med at $499 per month. Novo had only launched the cheaper ...

The Illinois basketball team got a lift from big man Tomislav Ivisic early in its first-round NCAA Tournament game against Xavier. The versatile 7-foot-1, 255-pound center averaged 12.5 points and ...

The 7 foot 1 center played in 32 games and started 31 one of them for the Orange and Blue last season. He averaged 13 points per game, 7.7 rebounds and shot just under 50 percent from the field ...

Tomislav Ivišić first announced his return to Illinois on Saturday, posting a photo of himself in an Illini jersey on Instagram with the words “I’m back” in orange across the top.

HYDERABAD, April 7 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with ...

LONDON, March 24 (Reuters) - German software company SAP (SAPG.DE), opens new tab overtook Danish healthcare company Novo Nordisk (NOVOb.CO), opens new tab as Europe's largest company by market ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...

Novo Holdings, the controlling shareholder of obesity drugmaker Novo Nordisk, nearly doubled annual income and investment returns to a record €8 billion in 2024, it said today. Fuelled by ...

Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, the active ingredient in its weight-loss drugs Ozempic and Wegovy, to lower heart ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity drug, the Danish Ozempic maker’s latest move to refill its pipeline ...